Secreted Gaussia Luciferase as a Biomarker for Monitoring Tumor Progression and Treatment Response of Systemic Metastases
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: Currently, only few techniques are available for quantifying systemic metastases in preclinical model. Thus techniques that can sensitively detect metastatic colonization and assess treatment response in real-time are urgently needed. To this end, we engineered tumor cells to express a naturally secreted Gaussia luciferase (Gluc), and investigated its use as a circulating biomarker for monitoring viable metastatic or primary tumor growth and their treatment responses. METHODOLOGY/PRINCIPAL FINDINGS: We first developed orthotopic primary and metastatic breast tumors with derivative of MDA-MB-231 cells expressing Gluc. We then correlated tumor burden with Gluc activity in the blood and urine along with bioluminescent imaging (BLI). Second, we utilized blood Gluc assay to monitor treatment response to lapatinib in an experimental model of systemic metastasis. We observed good correlation between the primary tumor volume and Gluc concentration in blood (R(2) = 0.84) and urine (R(2) = 0.55) in the breast tumor model. The correlation deviated as a primary tumor grew due to a reduction in viable tumor fraction. This was also supported by our mathematical models for tumor growth to compare the total and viable tumor burden in our model. In the experimental metastasis model, we found numerous brain metastases as well as systemic metastases including bone and lungs. Importantly, blood Gluc assay revealed early growth of metastatic tumors before BLI could visualize their presence. Using secreted Gluc, we localized systemic metastases by BLI and quantitatively monitored the total viable metastatic tumor burden by blood Gluc assay during the course of treatment with lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2. CONCLUSION/SIGNIFICANCE: We demonstrated secreted Gluc assay accurately reflects the amount of viable cancer cells in primary and metastatic tumors. Blood Gluc activity not only tracks metastatic tumor progression but also serves as a longitudinal biomarker for tumor response to treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The biology of brain metastases—translation to new therapies
Eichler, A. F., Chung, E., Kodack, D. P., Loeffler, J. S., Fukumura, D., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.58 · Cited by 567
Self-citationHall, B. M., Balan, V., Gleiberman, A. S., Strom, E., Krasnov, P., Virtuoso, L. P., Rydkina, E., Vujcic, S., Balan, K., Gitlin, I., et al. (2016) · Aging · doi:10.18632/aging.100991 · Cited by 357
Cancer imaging by optical coherence tomography: preclinical progress and clinical potential
Vakoc, B. J., Fukumura, D., Jain, R. K., & Bouma, B. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3235 · Cited by 299
Self-citationRahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5219 · Cited by 258
“Tumor burden was assessed bymeasuring blood concentration ofGaussia luciferase (Gluc) fromGluc-transduced tumors (73, 74) or using a highfrequency ultrasound imaging system (VisualSonics).”
MethodSelf-citationTargeting miR-21 for the Therapy of Pancreatic Cancer
Sicard, F., Gayral, M., Lulka, H., Buscail, L., & Cordelier, P. (2013) · Molecular Therapy · doi:10.1038/mt.2013.35 · Cited by 217
Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles
Stephan, M. T., Stephan, S. B., Bak, P., Chen, J., & Irvine, D. J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.04.029 · Cited by 209
“We retrovirally transduced tumor cell clones isolated from these cultures with a secreted Gaussia luciferase (sGau-Luc) gene [32] (Fig.”
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93182 · Cited by 164
Self-citationKodack, D. P., Chung, E., Yamashita, H., Incio, J., Duyverman, A. M. M. J., Song, Y., Farrar, C. T., Huang, Y., Ager, E., Kamoun, W., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216078109 · Cited by 153
“BT474 cells were transduced with an expression cassette encoding Gluc and CFP separated by an internal ribosomal entry site, using a lentiviral vector as previously described (24, 38).”
MethodSelf-citationJung, K., Heishi, T., Incio, J., Huang, Y., Beech, E. Y., Pinter, M., Ho, W. W., Kawaguchi, K., Rahbari, N. N., Chung, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710754114 · Cited by 138
Self-citationHata, A. N., Yeo, A., Faber, A. C., Lifshits, E., Chen, Z., Cheng, K. A., Walton, Z., Sarosiek, K. A., Letai, A., Heist, R. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3728 · Cited by 74
“Prior to implantation, these cells were modified to express Gaussia luciferase, which is secreted into the blood allowing for precise quantitation of tumor cell viability (Reference (27) and Figure S6).”
Metadata
- Authors
- Chung, E., Yamashita, H., Au, P., Tannous, B. A., Fukumura, D., & Jain, R. K.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-12-15
- Volume
- 4
- Issue
- 12
- Pages
- e8316
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2083797848
- Cited by
- 100
- References
- 0
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.